New potential for enhancing concomitant chemoradiotherapy with FDA approved concentrations of cisplatin via the photoelectric effect |
| |
| Affiliation: | 1. Department of Pathology, University of Oklahoma Health Sciences Center, 975 NE 10th Street, BRC 411A, Oklahoma City, OK 73104, USA;2. Department of Radio-Oncology, Nanjing Medical University Affiliated Suzhou Hospital, Suzhou, P. R. China;3. Departments of Pathology and Medicine, University of Colorado School of Medicine, Aurora, CO, USA |
| |
| Abstract: | We predict, for the first time, that by using United States Food and Drug Administration approved concentrations of cisplatin, major radiosensitization may be achieved via photoelectric mechanism during concomitant chemoradiotherapy (CCRT). Our analytical calculations estimate that radiotherapy (RT) dose to cancer cells may be enhanced via this mechanism by over 100% during CCRT. The results proffer new potential for significantly enhancing CCRT via an emerging clinical scenario, where the cisplatin is released in-situ from RT biomaterials loaded with cisplatin nanoparticles. |
| |
| Keywords: | Cisplatin nanoparticles Dose enhancement Chemoradiotherapy Radiotherapy Brachytherapy |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
